<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383746</url>
  </required_header>
  <id_info>
    <org_study_id>P100701</org_study_id>
    <nct_id>NCT01383746</nct_id>
  </id_info>
  <brief_title>Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION</brief_title>
  <acronym>CHOLANGIOSIR</acronym>
  <official_title>Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholangiocarcinoma (CCK) is a rare tumor (2000 new cases/year in France) with very poor
      prognosis (overall survival &lt; 3% at 5 years). Less than 20% of patients may benefit from
      curative surgical resection and most patients have medical treatment by palliative treatment
      by palliative chemotherapy. It is not standard first-line chemotherapy validated for
      unresectable CCK, but the best objective response rate (OR) and overall survival (OS) are
      observed with gemcitabine and platinum associations (OR 24 to 36% and OS between 9.5 to 15.4
      months). In case of tumor progression ater this first line therapy, no treatment is currently
      being validated.

      RADIOEMBOLIZATION (RE) is a new, transarterial approach to radiation therapy using 90 Yttrium
      microspheres.

      In the patients with unresectable CCK , the first pilot studies showed interesting results
      with rates of OR 45 to 90% and a median OS of 14.9 mots and an acceptable safety.

      Study Hypothesis : RE could help achieve tumor stabilization in patients with intra-hepatic
      CCK in tumor progression after first-line therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extended description of the protocol, including information not already contained in other
      fields, such as comparison studied.

      It is a pilot study including 20 patients with unresectable intra-hepatic CCK in tumor
      progression after first-line therapy.

      Description of the protocol :

        1. Information and signed CONSENTMENT

        2. Preparatory phase : pre-treatment mesenteric angiography and technetium-99m
           macroaggregated albumin scans are performed to assess gastrointestinal flow and lung
           shunting.

        3. Therapeutic phase : intra-arterial administration of resin-based microspheres (
           SIRSPHERES, SIRTEX). The RE can be performed in 2 sessions, especially if liver disease
           is bi-lobar.

        4. Follow up to J15,M1,M2,M4 and M6 : clinical examination and imaging evaluation ( scans
           and /or MRI)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough inclusion
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression -free survival at 6 months (from date of inclusion)</measure>
    <time_frame>6 months</time_frame>
    <description>Progression -free survival defined by the number of patients alive at 6 months without tumor progression documented on imaging evaluation ( MRI or CT) using RECIST criteria version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response at 1 month, 2 months, 4 months, 6 months</measure>
    <time_frame>1 month, 2 months, 4 months, 6 months</time_frame>
    <description>Tumor response documented on imaging evaluation (MRI or CT) using RECIST criteria version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of RADIOEMBOLIZATION using the NCI-CTCAE V3.0 classification.</measure>
    <time_frame>2 weeks, 1 month, 2 months, 4 months, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cholestasis, Progressive Familial Intrahepatic 3</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yttrium microsphere injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Yttrium microsphere injection</intervention_name>
    <description>Radiation therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable intra-hepatic CCK histologically proven

          -  Tumor progression documented on imaging evaluation ( CT or MRI) according to RECIST
             criteria version 1.1 after first-line therapy

          -  Performance status &lt; 2 ; 4) Bilirubin &lt; 36 micromol/l

          -  age &gt; 18 years

        Exclusion Criteria:

          -  Extra-hepatic metastases

          -  Uncontrolled biliary obstruction

          -  Contra-indications to RE.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laetitia FARTOUX, MD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint Antoine. Service d'Hépatologie, Pole digestif.</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006 Jun 5;94(11):1751-8.</citation>
    <PMID>16736026</PMID>
  </reference>
  <reference>
    <citation>Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005 Oct 8;366(9493):1303-14. Review. Erratum in: Lancet. 2006 May 20;367(9523):1656.</citation>
    <PMID>16214602</PMID>
  </reference>
  <reference>
    <citation>Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001 Jun;33(6):1353-7.</citation>
    <PMID>11391522</PMID>
  </reference>
  <reference>
    <citation>Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2003 May;37(5):961-9. Review.</citation>
    <PMID>12717374</PMID>
  </reference>
  <reference>
    <citation>Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002 Nov;51 Suppl 6:VI1-9.</citation>
    <PMID>12376491</PMID>
  </reference>
  <reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </reference>
  <reference>
    <citation>Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B; EORTC Gastro Intestinal Tract Cancer Group. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005 Feb;41(3):398-403.</citation>
    <PMID>15691639</PMID>
  </reference>
  <reference>
    <citation>Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer. 2009 Dec 1;101(11):1846-52. doi: 10.1038/sj.bjc.6605377. Epub 2009 Nov 10.</citation>
    <PMID>19904267</PMID>
  </reference>
  <reference>
    <citation>André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628.</citation>
    <PMID>19238628</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>RADIOEMBOLIZATION</keyword>
  <keyword>tumor response</keyword>
  <keyword>progression-free survival</keyword>
  <keyword>safety</keyword>
  <keyword>second-line therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

